REFERENCES
1. D'Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res Microbiol. 2007;158:553-4.
2. Fong K, Wong CWY, Wang S, Delaquis P. How Broad Is Enough: The Host Range of Bacteriophages and Its Impact on the Agri-Food Sector. Phage (New Rochelle). 2021;2:83-91.
3. to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2. Lancet Infect Dis. 2024;24:e737.
4. Erez Z, Steinberger-Levy I, Shamir M, et al. Communication between viruses guides lysis-lysogeny decisions. Nature. 2017;541:488-93.
5. McNair K, Bailey BA, Edwards RA. PHACTS, a computational approach to classifying the lifestyle of phages. Bioinformatics. 2012;28:614-8.
6. Summers WC. Cholera and plague in India: the bacteriophage inquiry of 1927-1936. J Hist Med Allied Sci. 1993;48:275-301.
7. Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19:35-45.
8. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730-3.
9. Haddad L, Mendoza JF, Jobin C. Bacteriophage-mediated manipulations of microbiota in gastrointestinal diseases. Front Microbiol. 2022;13:1055427.
10. 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400:2221-48.
11. Hibstu Z, Belew H, Akelew Y, Mengist HM. Phage therapy: a different approach to fight bacterial infections. Biologics. 2022;16:173-86.
12. Kaabi SAG, Musafer HK. An experimental mouse model for phage therapy of bacterial pathogens causing bacteremia. Microb Pathog. 2019;137:103770.
13. Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25:219-32.
14. Du D, Wang-Kan X, Neuberger A, et al. Multidrug efflux pumps: structure, function and regulation. Nat Rev Microbiol. 2018;16:523-39.
15. Liu H, Li H, Liang Y, et al. Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria. Theranostics. 2020;10:6310-21.
16. Verma V, Harjai K, Chhibber S. Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae. Biofouling. 2010;26:729-37.
17. Tan X, Chen H, Zhang M, et al. Clinical experience of personalized phage therapy against carbapenem-resistant acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Front Cell Infect Microbiol. 2021;11:631585.
18. Li C, Shi T, Sun Y, Zhang Y. A novel method to create efficient phage cocktails via use of phage-resistant bacteria. Appl Environ Microbiol. 2022;88:e0232321.
19. Uyttebroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22:e208-20.
20. Chen Q, Dharmaraj T, Cai PC, et al. Bacteriophage and bacterial susceptibility, resistance, and tolerance to antibiotics. Pharmaceutics. 2022;14:1425.
21. De Soir S, Parée H, Kamarudin NHN, et al. Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections. Microbiol Spectr. 2024;12:e0321923.
22. Pirnay JP, Djebara S, Steurs G, et al; Bacteriophage Therapy Providers. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 2024;9:1434-53.
23. Tagliaferri TL, Jansen M, Horz HP. Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy. Front Cell Infect Microbiol. 2019;9:22.
24. Stevens RH, Zhang H, Kajsik M, et al. Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis. Front Med (Lausanne). 2023;10:1238147.
25. Smug BJ, Majkowska-Skrobek G, Drulis-Kawa Z. PhREEPred: Phage resistance emergence prediction web tool to foresee encapsulated bacterial escape from phage cocktail treatment. J Mol Biol. 2022;434:167670.
26. Cheng M, Zhang Y, Li X, et al. Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections. Sci Rep. 2017;7:10164.
27. Yehl K, Lemire S, Yang AC, et al. Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis. Cell. 2019;179:459-469.e9.
28. Dedrick RM, Guerrero Bustamante CA, Garlena RA, Pinches RS, Cornely K, Hatfull GF. Mycobacteriophage ZoeJ: A broad host-range close relative of mycobacteriophage TM4. Tuberculosis (Edinb). 2019;115:14-23.
29. Zajdowicz SLW. Diverse phage-encoded toxins and their role in bacterial ecology. In Hurst CJ, editor. The biological role of a virus. Advances in environmental microbiology, vol 9. Cham: Springer International Publishing; 2022. p. 173-207.
30. Talbert JN, Alcaine SD, Nugen SR. Engineering bacteriophage for a pragmatic low-resource setting bacterial diagnostic platform. Bioengineered. 2016;7:132-6.
31. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61:e00954-17.
32. Nick JA, Dedrick RM, Gray AL, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022;185:1860-1874.e12.
33. Lebeaux D, Merabishvili M, Caudron E, et al. A case of phage therapy against pandrug-resistant achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses. 2021;13:60.
34. Doub JB, Shishido A, Srikumaran U, et al. Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection - a case report. Acta Orthop. 2022;93:756-9.
35. Li J, Yan B, He B, et al. Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence: a case report of a personalised phage therapy. Clin Microbiol Infect. 2023;29:1601.e1-7.
36. Racenis K, Rezevska D, Madelane M, et al. Use of phage cocktail BFC 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant pseudomonas aeruginosa femur osteomyelitis-a case report. Front Med (Lausanne). 2022;9:851310.
37. Torabi L, Doudi M, Naghavi NS, Monajemi R. Isolation, characterization, and effectiveness of bacteriophage Pɸ-Bw-Ab against XDR Acinetobacter baumannii isolated from nosocomial burn wound infection. Iran J Basic Med Sci. 2021;24:1254-63.
38. Teney C, Poupelin JC, Briot T, et al; PHAGEinLYON Clinic Study Group. Phage therapy in a burn patient colonized with extensively drug-resistant pseudomonas aeruginosa responsible for relapsing ventilator-associated pneumonia and bacteriemia. Viruses. 2024;16:1080.
39. Stellfox ME, Fernandes C, Shields RK, et al. Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia. mBio. 2024;15:e0339623.
40. Gainey AB, Daniels R, Burch AK, et al. Recurrent ESBL Escherichia coli urosepsis in a pediatric renal transplant patient treated with antibiotics and bacteriophage therapy. Pediatr Infect Dis J. 2023;42:43-6.
41. Le T, Nang SC, Zhao J, et al. Therapeutic potential of intravenous phage as standalone therapy for recurrent drug-resistant urinary tract infections. Antimicrob Agents Chemother. 2023;67:e0003723.
42. Qvist T, Eickhardt S, Kragh KN, et al. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. Eur Respir J. 2015;46:1823-6.
43. Yam YK, Alvarez N, Go ML, Dick T. Extreme drug tolerance of mycobacterium abscessus “persisters”. Front Microbiol. 2020;11:359.
44. Bogovazova GG, Voroshilova NN, Bondarenko VM. [The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh Mikrobiol Epidemiol Immunobiol. ;1991:5-8.
46. Abedon ST, Danis-Wlodarczyk KM, Wozniak DJ. Phage cocktail development for bacteriophage therapy: toward improving spectrum of activity breadth and depth. Pharmaceuticals (Basel). 2021;14:1019.
47. Aslam S. Phage therapy in lung transplantation: current status and future possibilities. Clin Infect Dis. 2023;77:S416-22.
48. Aslam S, Courtwright AM, Koval C, et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 2019;19:2631-9.
49. Jaja BNR, Jiang F, Badhiwala JH, et al. Association of pneumonia, wound infection, and sepsis with clinical outcomes after acute traumatic spinal cord injury. J Neurotrauma. 2019;36:3044-50.
51. Patel JC, Mollitt DL, Tepas JJ 3rd. Infectious complications in critically injured children. J Pediatr Surg. 2000;35:1174-8.
52. Bhartiya SK, Prasad R, Sharma S, Shukla V, Nath G, Kumar R. Biological therapy on infected traumatic wounds: a case-control study. Int J Low Extrem Wounds. 2024;23:504-12.
53. Garner MR, Sethuraman SA, Schade MA, Boateng H. Antibiotic prophylaxis in open fractures: evidence, evolving issues, and recommendations. J Am Acad Orthop Surg. 2020;28:309-15.
54. Sudduth JD, Moss JA, Spitler CA, et al. Open fractures: are we still treating the same types of infections? Surg Infect (Larchmt). 2020;21:766-72.
55. Onsea J, Soentjens P, Djebara S, et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11:891.
56. Chopra H, Islam MA, Sharun K, Emran TB, Al-Tawfiq JA, Dhama K. Recent advances in the treatment of biofilms induced surgical site infections. Int J Surg. 2023;109:65-7.
58. Nadareishvili L, Hoyle N, Nakaidze N, et al. Bacteriophage therapy as a potential management option for surgical wound infections. Phage (New Rochelle). 2020;1:158-65.
59. Kalan LR, Brennan MB. The role of the microbiome in nonhealing diabetic wounds. Ann N Y Acad Sci. 2019;1435:79-92.
60. Jasim HN, Hafidh RR, Abdulamir AS. Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study. Iran J Basic Med Sci. 2018;21:1100-8.
61. Jackson KR, Motter JD, Bae S, et al. Characterizing the landscape and impact of infections following kidney transplantation. Am J Transplant. 2021;21:198-207.
62. Coussement J, Kamar N, Matignon M, et al; Bacteriuria in Renal Transplantation (BiRT) study group. Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. Clin Microbiol Infect. 2021;27:398-405.
63. Kim P, Sanchez AM, Penke TJR, et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect Dis. 2024;24:1319-32.
64. Lee D, Im J, Kim AR, Jun W, Yun CH, Han SH. Enterococcus phage vB_EfaS_HEf13 as an anti-biofilm agent against enterococcus faecalis. J Microbiol. 2024;62:683-93.
65. Wolfoviz-Zilberman A, Kraitman R, Hazan R, Friedman M, Houri-Haddad Y, Beyth N. Phage targeting streptococcus mutans in vitro and in vivo as a caries-preventive modality. Antibiotics (Basel). 2021;10:1015.
66. Liu H, Yu Y, Dong A, Elsabahy M, Yang YW, Gao H. Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: systematic review, improvements and future challenges. Exploration (Beijing). 2024;4:20230092.
67. Petrov G, Dymova M, Richter V. Bacteriophage-mediated cancer gene therapy. Int J Mol Sci. 2022;23:14245.
68. Zheng DW, Dong X, Pan P, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat Biomed Eng. 2019;3:717-28.
69. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol. 2012;12:479-91.
70. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315-7.
71. da Fonseca Alves R, Pallarès-Rusiñol A, Rossi R, et al. Peptide-based biosensing approaches for targeting breast cancer-derived exosomes. Biosens Bioelectron. 2024;255:116211.
72. Vidal-Calvo EE, Martin-Salazar A, Choudhary S, et al. Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Nat Commun. 2024;15:7553.
73. Gray BP, Li S, Brown KC. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug Chem. 2013;24:85-96.
74. Sánchez-Navarro M, Teixidó M, Giralt E. Jumping hurdles: peptides able to overcome biological barriers. Acc Chem Res. 2017;50:1847-54.
75. Wang L, Li H, Wang X, et al. Modification of low-energy surfaces using bicyclic peptides discovered by phage display. J Am Chem Soc. 2023;145:17613-20.
76. Huang W, Soeung V, Boragine DM, Palzkill T. Mapping protein-protein interaction interface peptides with Jun-Fos assisted phage display and deep sequencing. ACS Synth Biol. 2020;9:1882-96.
77. Mimmi S, Maisano D, Quinto I, Iaccino E. Phage display: an overview in context to drug discovery. Trends Pharmacol Sci. 2019;40:87-91.
78. Pung HS, Tye GJ, Leow CH, Ng WK, Lai NS. Generation of peptides using phage display technology for cancer diagnosis and molecular imaging. Mol Biol Rep. 2023;50:4653-64.
79. Hampton JT, Liu WR. Diversification of phage-displayed peptide libraries with noncanonical amino acid mutagenesis and chemical modification. Chem Rev. 2024;124:6051-77.
80. Chen PC, Guo XS, Zhang HE, et al. Leveraging a phage-encoded noncanonical amino acid: a novel pathway to potent and selective epigenetic reader protein inhibitors. ACS Cent Sci. 2024;10:782-92.
81. Zhang Y. Evolution of phage display libraries for therapeutic antibody discovery. MAbs. 2023;15:2213793.
82. Ravn U, Didelot G, Venet S, et al. Deep sequencing of phage display libraries to support antibody discovery. Methods. 2013;60:99-110.
83. Ledsgaard L, Ljungars A, Rimbault C, et al. Advances in antibody phage display technology. Drug Discov Today. 2022;27:2151-69.
84. Hung LY, Wang CH, Fu CY, Gopinathan P, Lee GB. Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics. Lab Chip. 2016;16:2759-74.
85. Wang R, Li HD, Cao Y, Wang ZY, Yang T, Wang JH. M13 phage: a versatile building block for a highly specific analysis platform. Anal Bioanal Chem. 2023;415:3927-44.
86. Qin Y, Cheng S, Li Y, et al. The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma. Biomater Sci. 2020;8:5656-65.
87. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031-5.
88. Yao P, Gao M, Hu W, et al. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer. Pharmacol Res. 2024;204:107209.
89. Lawitz EJ, Fraessdorf M, Neff GW, et al; NCT05296733 Investigators. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024;81:837-46.
90. Li C, Li J, Xu Y, et al. Application of phage-displayed peptides in tumor imaging diagnosis and targeting therapy. Int J Pept Res Ther. 2021;27:587-95.
91. Larimer BM, Thomas WD, Smith GP, Deutscher SL. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display. Mol Imaging Biol. 2014;16:449-58.
92. Kumar SR, Deutscher SL. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med. 2008;49:796-803.
93. Dijkgraaf I, Terry SY, McBride WJ, et al. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide. Contrast Media Mol Imaging. 2013;8:238-45.
94. Liu S, Hsieh WY, Jiang Y, et al. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem. 2007;18:438-46.
95. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25:2433-46.
96. Tripathi PP, Arami H, Banga I, Gupta J, Gandhi S. Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy. Oncotarget. 2018;9:37252-67.
97. Schmid P, Adams S, Rugo HS, et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-21.
98. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218-30.
99. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-73.
100. Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-9.
101. Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based Cost. JAMA Oncol. 2015;1:1293-300.
102. Paz-Ares L, Mezger J, Ciuleanu TE, et al; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015;16:328-37.
103. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117-28.
104. Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345-56.
105. Nash P, Kirkham B, Okada M, et al; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317-27.
106. Mease PJ, Rahman P, Gottlieb AB, et al; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126-36.
107. Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32:1768-77.
108. Yurkiewicz IR, Coutre S, Ghesquieres H, Pastan I, Kreitman RJ. Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. Leuk Lymphoma. 2021;62:2812-4.
109. Scully M, Cataland SR, Peyvandi F, et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335-46.
110. Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137:733-42.
111. Chandrakasan S, Jordan MB, Baker A, et al. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024;8:2248-58.
112. Verkamp B, Jodele S, Sabulski A, Marsh R, Kieser P, Jordan MB. Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism. Blood. 2024;144:2625-36.
113. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
114. Tsai CW, Morris S. Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration “Animal Rule”. Front Microbiol. 2015;6:1320.
115. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361:135-44.
116. Banerji A, Riedl MA, Bernstein JA, et al; HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320:2108-21.
117. Pavoni E, Vaccaro P, Pucci A, et al. Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage. BMC Cancer. 2004;4:78.
118. Shi W, Yang X, Xie S, et al. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. Cancer Lett. 2021;522:184-97.
119. Li D, Wang R, Liang T, et al. Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours. Nat Commun. 2023;14:5920.
120. Campbell S, Suwan K, Waramit S, Aboagye EO, Hajitou A. Selective inhibition of histone deacetylation in melanoma increases targeted gene delivery by a bacteriophage viral vector. Cancers (Basel). 2018;10:125.
121. Przystal JM, Waramit S, Pranjol MZI, et al. Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma. EMBO Mol Med. 2019;11:e8492.
122. Wu LP, Ahmadvand D, Su J, et al. Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. Nat Commun. 2019;10:4635.
123. Wang T, Hartner WC, Gillespie JW, et al. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein. Nanomedicine. 2014;10:421-30.
124. Xiao L, Ma N, He H, et al. Development of a novel drug targeting delivery system for cervical cancer therapy. Nanotechnology. 2019;30:075604.
125. Magaziner SJ, Salmond GPC. A novel T4- and λ-based receptor binding protein family for bacteriophage therapy host range engineering. Front Microbiol. 2022;13:1010330.
126. Lin J, Du F, Long M, Li P. Limitations of phage therapy and corresponding optimization strategies: a review. Molecules. 2022;27:1857.
127. Zaczek-Moczydłowska MA, Young GK, Trudgett J, et al. Phage cocktail containing Podoviridae and Myoviridae bacteriophages inhibits the growth of Pectobacterium spp. under in vitro and in vivo conditions. PLoS One. 2020;15:e0230842.
128. Tetz GV, Ruggles KV, Zhou H, Heguy A, Tsirigos A, Tetz V. Bacteriophages as potential new mammalian pathogens. Sci Rep. 2017;7:7043.
129. Rendueles O, de Sousa JAM, Rocha EPC. Competition between lysogenic and sensitive bacteria is determined by the fitness costs of the different emerging phage-resistance strategies. Elife. 2023;12:e83479.
130. Bernheim A, Sorek R. The pan-immune system of bacteria: antiviral defence as a community resource. Nat Rev Microbiol. 2020;18:113-9.
131. Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10:351.
132. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016;6:26717.
133. Kortright KE, Chan BK, Evans BR, Turner PE. Arms race and fluctuating selection dynamics in Pseudomonas aeruginosa bacteria coevolving with phage OMKO1. J Evol Biol. 2022;35:1475-87.
134. Baqer AA, Fang K, Mohd-Assaad N, Adnan SNA, Md Nor NS. In vitro activity, stability and molecular characterization of eight potent bacteriophages infecting carbapenem-resistant klebsiella pneumoniae. Viruses. 2022;15:117.
135. Fister S, Robben C, Witte AK, Schoder D, Wagner M, Rossmanith P. Influence of environmental factors on phage-bacteria interaction and on the efficacy and infectivity of phage P100. Front Microbiol. 2016;7:1152.
136. Matsuda T, Freeman TA, Hilbert DW, et al. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery. 2005;137:639-46.
137. Topka-Bielecka G, Dydecka A, Necel A, et al. Bacteriophage-derived depolymerases against bacterial biofilm. Antibiotics (Basel). 2021;10:175.
138. Johansson ME, Ambort D, Pelaseyed T, et al. Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci. 2011;68:3635-41.
139. Kim SG, Giri SS, Yun S, et al. Synergistic phage-surfactant combination clears IgE-promoted Staphylococcus aureus aggregation in vitro and enhances the effect in vivo. Int J Antimicrob Agents. 2020;56:105997.
140. Porter SB, Johnston BD, Kisiela D, Clabots C, Sokurenko EV, Johnson JR. Bacteriophage cocktail and microcin-producing probiotic Escherichia coli protect mice against gut colonization with multidrug-resistant Escherichia coli sequence type 131. Front Microbiol. 2022;13:887799.
141. Gelman D, Yerushalmy O, Alkalay-Oren S, et al. Clinical phage microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy. Lancet Microbe. 2021;2:e555-63.
142. Kaneko T, Osaka T, Tsuneda S. Tailoring effective phage cocktails for long-term lysis of escherichia coli based on physiological properties of constituent phages. Phage (New Rochelle). 2023;4:128-35.
143. Vázquez R, Díez-Martínez R, Domingo-Calap P, et al. Essential topics for the regulatory consideration of phages as clinically valuable therapeutic agents: a perspective from Spain. Microorganisms. 2022;10:717.
144. Nagel T, Musila L, Muthoni M, Nikolich M, Nakavuma JL, Clokie MR. Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Curr Opin Virol. 2022;53:101208.
145. Le S, Wei L, Wang J, et al. Bacteriophage protein Dap1 regulates evasion of antiphage immunity and Pseudomonas aeruginosa virulence impacting phage therapy in mice. Nat Microbiol. 2024;9:1828-41.
146. Kassa T. Bacteriophages against pathogenic bacteria and possibilities for future application in Africa. Infect Drug Resist. 2021;14:17-31.
147. Yerushalmy O, Braunstein R, Alkalay-Oren S, et al. Towards standardization of phage susceptibility testing: the Israeli phage therapy center “clinical phage microbiology”-a pipeline proposal. Clin Infect Dis. 2023;77:S337-51.
148. Khatami A, Foley DA, Warner MS, et al; Phage Australia Clinical Network. Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial. BMJ Open. 2022;12:e065401.
